NYSE: CNOCno Financial Group Inc Stock
$54.85+0.57 (+1.05%)
Updated Aug 13, 2026
CNO Price
$54.85
Fair Value Price
N/A
Market Cap
$5.07B
52 Week Low
$37.36
52 Week High
$57.59
P/E
18.53x
P/B
1.96x
P/S
1.02x
PEG
0.8x
Dividend Yield
1.26%
Revenue
$4.65B
Earnings
$279.60M
Gross Margin
45%
Operating Margin
12.3%
Profit Margin
6%
Debt to Equity
14.38
Operating Cash Flow
$699M
Beta
0.92
Next Earnings
N/A
Ex-Dividend
Sep 10, 2026
Next Dividend
Sep 24, 2026
CNO Overview
CNO Financial Group, Inc. offers health insurance, annuities, individual life insurance, and other insurance products to senior and middle-income markets. The majority of its revenue is from its Bankers Life segment which underwrites Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities, and long-term care insurance products. CNO Financial Group, Inc. was founded in 1979 and is headquartered in Carmel, IA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CNO's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +17.17% per year. Learn More
Zen Rating Component Grades
A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Property & Casualty Insurance
Industry Rating
B
CNO
Ranked#2 of 20
Ranked#2 of 20
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $134.38 | B | |
| $97.47 | C | |
| $124.75 | C |
Be the first to know about important CNO news, forecast changes, insider trades & much more!
CNO News
Overview
Due Diligence Score
–
Industry Average (40)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CNO scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNO ($54.85) is trading above its intrinsic value of $36.91, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CNO is poor value based on its earnings relative to its share price (18.53x), compared to the US market average (14.17x)
P/E vs Market Valuation
CNO is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CNO due diligence checks available for Premium users.
Valuation
CNO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
18.53x
Industry
17.6x
Market
14.17x
CNO is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CNO is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
CNO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.96x
Industry
1.65x
CNO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNO price to earnings growth (PEG)
For valuing profitable companies with growth potential
CNO is good value based... subscribe to Premium to read more.
PEG Value Valuation
CNO's financial health
Profit margin
Revenue
$1.3B
Net Income
$125.9M
Profit Margin
9.8%
CNO's Earnings (EBIT) of $571.70M... subscribe to Premium to read more.
Interest Coverage Financials
CNO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$39.9B
Liabilities
$37.3B
Debt to equity
14.38
CNO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CNO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$156.6M
Investing
-$603.7M
Financing
$598.8M
CNO's operating cash flow ($698.90M)... subscribe to Premium to read more.
Debt Coverage Financials
CNO vs Property & Casualty Insurance Stocks
Cno Financial Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.